1	SARS-CoV-2-specific T Cell Memory is Sustained in COVID-19 Convalescents for 8 Months
2	with Successful Development of Stem Cell-like Memory T Cells
3	
4	Jae Hyung Jung <sup>1†</sup> , Min-Seok Rha <sup>1†</sup> , Moa Sa <sup>1,2</sup> , Hee Kyoung Choi <sup>3</sup> , Ji Hoon Jeon <sup>3</sup> , Hyeri Seok <sup>3</sup> ,
5	Dae Won Park <sup>3</sup> , Su-Hyung Park <sup>1,2</sup> , Hye Won Jeong <sup>4*</sup> , Won Suk Choi <sup>3*</sup> , Eui-Cheol Shin <sup>1,2*</sup>
6	
7	<sup>1</sup> Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science
8	and Technology (KAIST), Daejeon 34141, Republic of Korea
9	<sup>2</sup> The Center for Epidemic Preparedness, KAIST Institute, Daejeon 34141, Republic of Korea
10	<sup>3</sup> Division of Infectious Diseases, Department of Internal Medicine, Korea University College
11	of Medicine, Ansan Hospital, Ansan 15355, Republic of Korea
12	<sup>4</sup> Department of Internal Medicine, Chungbuk National University College of Medicine,
13	Cheongju 28644, Republic of Korea
14	
15	<sup>†</sup> These authors contributed equally.
16	
17	*Corresponding authors
18	Eui-Cheol Shin, M.D., Ph.D., e-mail: <u>ecshin@kaist.ac.kr</u>
19	Won Suk Choi, M.D., Ph.D., e-mail: <u>cmcws@korea.ac.kr</u>

20 Hye Won Jeong, M.D., Ph.D., e-mail: hwjeong@chungbuk.ac.kr

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

#### 21 Abstract

22 Memory T cells contribute to rapid viral clearance during re-infection, but the longevity and differentiation of SARS-CoV-2-specific memory T cells remain unclear. We conducted direct 23 ex vivo assays to evaluate SARS-CoV-2-specific CD4<sup>+</sup> and CD8<sup>+</sup> T cell responses in COVID-19 2425 convalescents up to 254 days post-symptom onset (DPSO). Here, we report that memory T 26 cell responses were maintained during the study period. In particular, we observed sustained polyfunctionality and proliferation capacity of SARS-CoV-2-specific T cells. Among 2728 SARS-CoV-2-specific CD4<sup>+</sup> and CD8<sup>+</sup> T cells detected by activation-induced markers, the 29 proportion of stem cell-like memory T (T<sub>SCM</sub>) cells increased, peaking at approximately 120 DPSO. Development of T<sub>SCM</sub> cells was confirmed by SARS-CoV-2-specific MHC-I multimer 30 staining. Considering the self-renewal capacity and multipotency of T<sub>SCM</sub> cells, our data 31 32 suggest that SARS-CoV-2-specific T cells are long-lasting after recovery from COVID-19. The 33 current study provides insight for establishing an effective vaccination program and 34 epidemiological measurement.

#### 35 Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection causes 36 coronavirus disease 2019 (COVID-19), an ongoing pandemic disease that threatens public 37 health<sup>1</sup>. As of January 17, 2021, more than 93.2 million confirmed cases had been reported, 38 39 and over 2 million deaths worldwide<sup>2</sup>. After SARS-CoV-2 infection, some patients, 40 particularly elderly patients, develop severe COVID-19 that is associated with hyperinflammatory responses<sup>3,4</sup>. Global efforts are underway to prevent the transmission of SARS-41CoV-2 and to develop novel vaccines and therapeutic strategies. A thorough understanding 42 of the immune responses against SARS-CoV-2 is urgently needed to control the COVID-19 43 pandemic. 44

Increasing evidence has demonstrated that SARS-CoV-2-specific memory T cell 45 46 responses are elicited after recovery from COVID-19. A number of studies have reported 47SARS-CoV-2-specific memory T cell responses in the early convalescent phase of COVID-19<sup>5-9</sup>. SARS-CoV-2-specific CD4<sup>+</sup> and CD8<sup>+</sup> T cells have been detected in 100% and ~70% of 48convalescent individuals a short time after resolution<sup>5</sup>. Recently, memory T cells were shown 49 to contribute to protection against SARS-CoV-2 re-challenge in a rhesus macaque model<sup>10</sup>. 50 Considering that T cell responses to SARS-CoV-1 and Middle East respiratory syndrome 51 coronavirus (MERS-CoV) are long-lasting, up to >17 years<sup>6,11-13</sup>, SARS-CoV-2-specific memory 52 T cells are expected to be maintained long-term and to contribute to rapid viral clearance 53 during re-infection. A very recent study has examined SARS-CoV-2-specific T cell responses 54 55 up to 8 months after infection using activation-induced marker (AIM) assays<sup>14</sup>.

56 Following natural infection or vaccination, the generation of effective and persistent T cell memory is essential for long-term protective immunity to the virus. Among diverse 57 memory T cell subsets, stem cell-like memory T ( $T_{SCM}$ ) cells were recently reported to have 58 the capacity for self-renewal and multipotency to repopulate the broad spectrum of 59 memory and effector T cell subsets<sup>15,16</sup>. Thus, the successful generation of T<sub>SCM</sub> cells is 60 required for long-term protective T cell immunity<sup>16</sup>. For example, long-lived memory T cells 61 following vaccination with live-attenuated yellow fever virus (YFV) exhibit stem cell-like 62 properties and mediate lifelong protection<sup>17,18</sup>. However, limited knowledge is available on 63 the differentiation of SARS-CoV-2-specific memory T cells following recovery from COVID-19, 64 particularly the generation of  $T_{SCM}$  cells. 65

In the present study, we performed a comprehensive analysis of SARS-CoV-2-specific 66 CD4<sup>+</sup> and CD8<sup>+</sup> T cell responses in peripheral blood mononuclear cells (PBMCs) from 67 individuals with SARS-CoV-2 infection over 8 months post-infection. Using diverse T cell 68 assays, we found that SARS-CoV-2-specific memory T cell responses were maintained 8 69 70 months after the infection. In addition, we analyzed the differentiation of SARS-CoV-2specific memory T cells during the study period and revealed the successful generation of 7172 T<sub>SCM</sub> cells. We also assessed the effector functions and proliferation capacity of long-term memory CD4<sup>+</sup> and CD8<sup>+</sup> T cells. 73

#### 74Results

#### Study cohort 75

We recruited 94 individuals with SARS-CoV-2 infection. The peak disease severity 76 was evaluated according to the NIH severity of illness categories<sup>19</sup>: asymptomatic (n=6), mild 77 78(n=44), moderate (n=23), severe (n=13), and critical (n=8). Whole blood samples were 79 obtained longitudinally (2-4 time points) from 38 patients or at a single time point from 56 patients. Whole blood was collected 1 to 254 days post-symptom onset (DPSO). Finally, a 80 total of 160 PBMC samples were analyzed. Among 160 PBMC samples, 33 samples were 81 82 obtained in the acute phase when viral RNA was still detected (1 - 33 DPSO), and 127 samples were obtained in the convalescent phase after the negative conversion of viral RNA 83 (31 - 254 DPSO). In the current study, we defined the acute phase as 1 - 30 DPSO, and the 84 convalescent phase as 31 - 254 DPSO. The demographic and clinical characteristics of 85 86 enrolled patients are presented in Supplementary Table 1.

87

#### 88

#### SARS-CoV-2-specific T cell responses are sustained 8 months after the infection

First, we performed direct *ex vivo* interferon- $\gamma$  (IFN- $\gamma$ ) enzyme-linked immunospot 89 (ELISpot) assays following stimulation of PBMCs with overlapping peptide (OLP) pools 90 spanning the spike (S), membrane (M), and nucleocapsid (N) proteins of SARS-CoV-2. S-, M-, 91 and N-specific IFN- $\gamma$  spot numbers increased during the acute phase. Subsequently, there 92 was a decreasing tendency until 60 - 120 DPSO, and the IFN- $\gamma$  responses were maintained 93 over 8 months (Fig. 1a). These kinetics were also observed when S-, M-, and N-specific IFN- $\gamma$ 94 spot numbers were summed (Fig. 1a). In each PBMC sample, all three OLP pools evenly 95 contributed to the IFN- $\gamma$  responses without antigen dominance (Fig. 1b). We divided 96 convalescent samples into three groups based on the DPSO at sample collection: T1 (31 - 99 97 DPSO), T2 (100 - 199 DPSO), and T3 (200 - 254 DPSO). We found no significant difference in 98 99 IFN- $\gamma$  spot numbers among groups (Fig. 1c), and an even contribution of antigens for the IFN-100  $\gamma$  response was maintained among groups (Extended Data Fig. 1). Next, we focused on longitudinally tracked samples from 30 individuals in the convalescent phase. S-, M-, and N-101 specific and summed IFN- $\gamma$  spot numbers were stable during the convalescent phase (Fig. 102 1d). When we compared paired samples from the same patient at two time points (t1, 31 -103 104 100 DPSO; t2, 200 - 254 DPSO), we found no significant difference in IFN- $\gamma$  spot numbers

105 (Fig. 1e).

We also evaluated SARS-CoV-2-specific T cell responses by AIM assays<sup>5,20,21</sup> following 106 stimulation of PBMCs with OLP pools of S, M, and N. CD137<sup>+</sup>OX40<sup>+</sup> cells were considered 107 SARS-CoV-2-specific cells among CD4<sup>+</sup> T cells, and CD137<sup>+</sup>CD69<sup>+</sup> cells were considered SARS-108 109 CoV-2-specific cells among CD8<sup>+</sup> T cells<sup>5</sup> (Fig. 2a, b). We confirmed a strong positive 110 correlation between the frequency of CD137<sup>+</sup>OX40<sup>+</sup> cells and the frequencies of alternative AIM<sup>+</sup> cells (OX40<sup>+</sup>CD154<sup>+</sup> or CD137<sup>+</sup>CD154<sup>+</sup> cells) among CD4<sup>+</sup> T cells (Extended Data Fig. 2). 111 The frequency of S-, M-, and N-specific CD137<sup>+</sup>OX40<sup>+</sup> cells among CD4<sup>+</sup> T cells increased 112 during the acute phase, decreased until 60 DPSO, and then was maintained over 8 months 113 (Fig. 2c). When the frequency of S-, M-, and N-specific CD137<sup>+</sup>OX40<sup>+</sup> cells was summed, 114similar kinetics were observed (Fig. 2c). The frequency of CD137<sup>+</sup>CD69<sup>+</sup> cells among CD8<sup>+</sup> T 115 cells was relatively low compared to the frequency of CD137<sup>+</sup>OX40<sup>+</sup> cells among CD4<sup>+</sup> T cells, 116 117 but exhibited similar kinetics (Fig. 2c). We also observed a positive correlation between the frequency of CD137<sup>+</sup>OX40<sup>+</sup> cells among CD4<sup>+</sup> T cells and the frequency of CD137<sup>+</sup>CD69<sup>+</sup> cells 118 among CD8<sup>+</sup> T cells (Extended Data Fig. 3). 119

Collectively, these results indicate that SARS-CoV-2-specific T cell responses are long lasting over 8 months in COVID-19 convalescents.

122

#### 123 SARS-CoV-2-specific T<sub>SCM</sub> cells develop after the infection

124 Next, we examined the differentiation status of SARS-CoV-2-specific AIM<sup>+</sup> T cells 125 based on CCR7 and CD45RA expression in CD4<sup>+</sup> (Fig. 3a) and CD8<sup>+</sup> (Fig. 3b) T cell populations. Among SARS-CoV-2-specific AIM<sup>+</sup>CD4<sup>+</sup> T cells, the proportion of CCR7<sup>+</sup>CD45RA<sup>-</sup> (T<sub>CM</sub>) cells 126 was maintained at approximately 50% on average during the study period, and the 127 proportion of CCR7<sup>-</sup>CD45RA<sup>-</sup> (T<sub>EM</sub>) cells increased up to approximately 35% on average until 128 60 DPSO and then maintained thereafter (Fig. 3c). CCR7<sup>-</sup>CD45RA<sup>+</sup> (T<sub>EMRA</sub>) cells were a minor 129 population (< 5%; Fig. 3c). Notably, the proportion of CCR7<sup>+</sup>CD45RA<sup>+</sup> cells, which include 130 both naïve and T<sub>SCM</sub> cells, was approximately 30% on average in the acute phase, decreasing 131 132 to approximately 10% on average by 60 DPSO and then maintained thereafter (Fig. 3c). Among SARS-CoV-2-specific AIM<sup>+</sup>CD8<sup>+</sup> T cells, the proportion of CCR7<sup>+</sup>CD45RA<sup>-</sup> (T<sub>CM</sub>) 133

cells was approximately 20% on average in the acute phase and gradually decreased during
 the study period (Fig. 3d). The proportion of CCR7<sup>-</sup>CD45RA<sup>-</sup> (T<sub>EM</sub>) cells increased up to 50%

on average until 60 DPSO and was maintained thereafter (Fig. 3d). The proportion of CCR7<sup>-</sup>
 CD45RA<sup>+</sup> (T<sub>EMRA</sub>) cells and CCR7<sup>+</sup>CD45RA<sup>+</sup> cells was maintained (~25% and 25-35% on

average, respectively) during the study period (Fig. 3d).

We further investigated whether CCR7<sup>+</sup>CD45RA<sup>+</sup> cells include T<sub>SCM</sub> cells, which have 139 a self-renewal capacity and multipotency for differentiation into diverse T cell subsets, by 140 examining CD95, a marker of T<sub>SCM</sub> cells<sup>15,16</sup>. In both AIM<sup>+</sup>CD4<sup>+</sup> and AIM<sup>+</sup>CD8<sup>+</sup> T cells, CD95<sup>+</sup> 141cells were a dominant population among CCR7<sup>+</sup>CD45RA<sup>+</sup> cells (Fig. 3e), indicating that the 142 CCR7<sup>+</sup>CD45RA<sup>+</sup> cells among AIM<sup>+</sup>CD4<sup>+</sup> or AIM<sup>+</sup>CD8<sup>+</sup> T cells are mainly T<sub>SCM</sub> cells. The 143 frequency of T<sub>SCM</sub> cells among both AIM<sup>+</sup>CD4<sup>+</sup> and AIM<sup>+</sup>CD8<sup>+</sup> T cells gradually increased until 144 120 DPSO, when it reached a stable plateau (Fig. 3e). We found no significant difference in 145 the frequency of T<sub>SCM</sub> cells among AIM<sup>+</sup>CD4<sup>+</sup> and AIM<sup>+</sup>CD8<sup>+</sup> T cells between T1 (31 - 99 146 147DPSO), T2 (100 - 199 DPSO), and T3 (200 - 254 DPSO; Extended Data Fig. 4a, b).

148

# Successful development of SARS-CoV-2-specific T<sub>SCM</sub> cells is confirmed by direct ex vivo MHC-I multimer staining

To validate the results from in vitro stimulation-based AIM assays, we detected 151 SARS-CoV-2-specific CD8<sup>+</sup> T cells by performing direct *ex vivo* MHC-I multimer staining and 152examined the differentiation status of MHC-I multimer<sup>+</sup> cells. We used an HLA-A\*02 153 multimer loaded with SARS-CoV-2 S269 (YLQPRTFLL) peptide that has a low degree of 154 homology to the human common cold coronaviruses (ccCoVs)<sup>22,23</sup>. MHC-I multimer<sup>+</sup> cells 155156 were detected during the study period until 234 DPSO (Fig. 4a, b), and we determined the proportions of T<sub>CM</sub> (CCR7<sup>+</sup>CD45RA<sup>-</sup>), T<sub>EM</sub> (CCR7<sup>-</sup>CD45RA<sup>-</sup>), T<sub>EMRA</sub> (CCR7<sup>-</sup>CD45RA<sup>+</sup>), and T<sub>SCM</sub> 157 (CCR7<sup>+</sup>CD45RA<sup>+</sup>CD95<sup>+</sup>) cells among MHC-I multimer<sup>+</sup> cells (Fig. 4c). Influenza A virus (IAV)-158and cytomegalovirus (CMV)-specific MHC-I multimers were also used to stain PBMCs from 159 healthy donors. Similar to the data from AIM<sup>+</sup>CD8<sup>+</sup> T cells, T<sub>EM</sub> and T<sub>EMRA</sub> cells were the 160 dominant populations among SARS-CoV-2-specific MHC-I multimer<sup>+</sup> cells, whereas T<sub>CM</sub> cells 161 were a minor population during the study period (Fig. 4d). Among IAV- and CMV-specific 162 163 MHC-I multimer<sup>+</sup> cells from healthy donors, T<sub>EM</sub> and T<sub>EMRA</sub> cells were dominantly present, whereas T<sub>CM</sub> cells were scarcely detected. T<sub>SCM</sub> cells were also detected among SARS-CoV-2-164 specific MHC-I multimer<sup>+</sup> cells during the study period, but not among IAV- and CMV-specific 165 cells (Fig. 4d). In particular, the frequency of T<sub>SCM</sub> cells among SARS-CoV-2-specific MHC-I 166

167 multimer<sup>+</sup> cells was high 60 – 125 DPSO.

168A recent study has revealed two distinct subsets of CCR7+ stem cell-like progenitors:169CCR7+PD-1-TIGIT- cells with stem cell-like features and CCR7+PD-1+TIGIT+ cells with exhausted170traits<sup>24</sup>. Therefore, we examined the expression of PD-1 and TIGIT in SARS-CoV-2-specific171MHC-I multimer+ T<sub>SCM</sub> cells. The frequency of PD-1+TIGIT+ cells was significantly lower among172SARS-CoV-2-specific T<sub>SCM</sub> cells than among total CD8+ T cells (Fig. 4e), confirming that SARS-173CoV-2-specific T<sub>SCM</sub> cells are *bona fide* stem-like memory cells.

174

#### 175 Polyfunctionality and proliferation capacity are preserved in long-term SARS-CoV-2-

#### 176 specific T cells

As we observed the generation of SARS-CoV-2-specific T<sub>SCM</sub> cells with self-renewal 177 capacity and multipotency, we aimed to examine the kinetics of the polyfunctionality of 178 SARS-CoV-2-specific T cells during the study period. To this end, we performed intracellular 179 180 cytokine staining of IFN- $\gamma$ , IL-2, TNF, and CD107a following stimulation with OLP pools of S, M, and N and analyzed the polyfunctionality of CD4<sup>+</sup> and CD8<sup>+</sup> T cells (Fig. 5a). We defined 181 polyfunctional cells as cells exhibiting positivity for  $\geq 2$  effector functions. Among SARS-CoV-182 183 2-specific CD4<sup>+</sup> and CD8<sup>+</sup> T cells, the average proportion of polyfunctional cells was 25 - 40% 184 and 30 - 50%, respectively, 60 DPSO, and was maintained until 254 DPSO (Fig. 5b). We found no significant difference in the frequency of polyfunctional cells among SARS-CoV-2-specific 185 CD4<sup>+</sup> and CD8<sup>+</sup> T cells between T1 (31 - 99 DPSO), T2 (100 - 199 DPSO), and T3 (200 - 254 186 DPSO; Fig. 5c). Preserved polyfunctionality among SARS-CoV-2-specific CD4<sup>+</sup> and CD8<sup>+</sup> T cells 187 was also observed when polyfunctionality was evaluated according to the number of 188 positive effector functions (Fig. 5d). 189

Finally, we examined the antigen-induced proliferation capacity of long-term SARS-190 191 CoV-2-specific memory T cells. We performed CellTrace Violet (CTV) dilution assays and Ki-67 staining using PBMCs obtained after 200 DPSO. CD4<sup>+</sup> T cells exhibited a robust 192 193 proliferative response following *in vitro* stimulation with the S OLP pool (Fig. 5e), indicating that SARS-CoV-2-specific memory T cells elicit rapid recall responses upon viral re-exposure. 194 195 Considering preserved polyfunctionality and proliferation capacity of SARS-CoV-2specific memory T cells, the current data indicate that memory T cells contribute to 196 protective immunity against re-infection even 8 months after the primary infection. 197

#### 198 **Discussion**

Memory T cells play a crucial role in viral clearance during re-infection, but the 199 longevity and differentiation status of SARS-CoV-2-specific memory T cells among COVID-19 200 convalescents remain unclear. In the present study, we demonstrated that SARS-CoV-2-201 202 specific memory T cell responses were maintained in COVID-19 convalescents 8 months 203 post-infection. Notably, we found that SARS-CoV-2-specific T<sub>SCM</sub> cells were successfully developed, indicating that SARS-CoV-2-specific T cell memory may be long-lasting in COVID-204 19 convalescents. These findings were supported by the SARS-CoV-2-specific T cells from 205 PBMCs obtained after 200 DPSO exhibiting sustained polyfunctionality and proliferation 206 capacity. Our results may fill a gap in understanding T cell memory responses after recovery 207 from SARS-CoV-2 infection. 208

Recent studies suggest critical roles of T cells in the clearance of SARS-CoV-2 and 209 210 protection from developing severe COVID-19. In particular, it has been shown that 211 coordination of adaptive immune responses, including CD4<sup>+</sup> T cell, CD8<sup>+</sup> T cell, and antibody responses, is essential for controlling COVID-19<sup>20</sup>. Notably, peak disease severity has been 212 shown to inversely correlate with the frequency of SARS-CoV-2-specific CD4<sup>+</sup> and CD8<sup>+</sup> T cells 213 instead of SARS-CoV-2 antibody titers<sup>20</sup>. In another study, T cell responses were detected 214 among COVID-19 convalescents without detectable SARS-CoV-2 IgG<sup>25</sup>. In a rhesus macaque 215 model, CD8-depleted convalescent animals exhibited limited viral clearance in the 216 217 respiratory tract upon SARS-CoV-2 re-challenge, suggesting that CD8<sup>+</sup> T cells contribute to viral clearance during SARS-CoV-2 re-infection<sup>10</sup>. Collectively, these studies strongly 218 219 demonstrate a protective role of T cells in COVID-19.

Currently, we do not have exact information on how long adaptive immune memory 220 221 lasts in COVID-19 convalescents. Whether antibody responses to SARS-CoV-2 wane over time in patients who have recovered from COVID-19 remains controversial<sup>26-28</sup>. Previous 222 223 studies on SARS-CoV-1 and MERS-CoV infection have shown that T cell responses were more 224 enduring compared to antibody responses<sup>12,13</sup>. A recent study detected SARS-CoV-1-specific 225 T cell responses 17 years after infection<sup>6</sup>. Similarly, slow decay of SARS-CoV-2-specific memory T cells is expected. In the present study, we demonstrated the maintenance of 226 SARS-CoV-2-specific memory T cell responses in COVID-19 convalescents over 8 months 227 post-infection using a battery of T cell assays. Given that vaccination programs for 228

prophylaxis of SARS-CoV-2 infection are being launched worldwide, another question is how
 long memory T cells elicited by vaccination will last. Vaccine-induced memory T cells may
 differ in phenotype and durability from infection-induced memory T cells, which should be
 addressed in future studies.

233 A series of studies have reported the existence of SARS-CoV-2-reactive T cell 234responses among unexposed individuals, suggesting that memory T cells induced by previous ccCoV infection are cross-reactive to SARS-CoV-2 proteins<sup>5,29-32</sup>. Therefore, in the 235 present study, we could not distinguish *de novo* primed T cells by SARS-CoV-2 infection from 236 pre-existing, cross-reactive ccCoV-specific T cells. However, we could selectively examine de 237 *novo* primed SARS-CoV-2-specific T cells by staining with an HLA-A\*02 multimer loaded with 238 239 SARS-CoV-2 S269 (YLQPRTFLL) peptide. This epitope peptide has a low degree of homology with ccCoVs, including OC43, HKU1, 229E, and NL63<sup>22,23</sup>. In future studies of SARS-CoV-2-240 241 specific T cell responses, cross-reactive epitope peptides and SARS-CoV-2-specific epitope peptides will need to be used separately<sup>30</sup>. 242

Among distinct subsets of memory T cells,  $T_{SCM}$  cells possess a superior ability for 243 self-renewal, memory recall responses, and multipotency to reconstitute diverse memory 244 subsets<sup>15</sup>. Therefore, long-term T cell memory relies on the successful generation of T<sub>SCM</sub> 245 246 cells<sup>16</sup>. Previous studies showed that long-lasting YFV-specific CD8<sup>+</sup> T cells resemble  $T_{SCM}$ cells<sup>17,18</sup>. We and others have also suggested the generation of SARS-CoV-2-specific  $T_{SCM}$  cells 247 in the convalescent phase of COVID-19 on the basis of the expression of CCR7 and 248 249 CD45RA<sup>8,23</sup>. However, these studies on COVID-19 patients did not examine the definitive 250 marker of T<sub>SCM</sub> cells, CD95. In the present study, we delineated the kinetics of T<sub>SCM</sub> cells using 251 both AIM assays and MHC-I multimer staining, and observed the successful generation of 252 T<sub>SCM</sub> cells in COVID-19 convalescents. In line with these findings, we also found sustained 253 polyfunctionality and proliferation capacity, suggesting efficient memory recall responses. A recent study has proposed that CCR7<sup>+</sup> stem-like progenitor cells are composed of two 254 separate populations, which are distinguished by PD-1 and TIGIT expression<sup>24</sup>. We 255 256 demonstrated that PD-1 and TIGIT are rarely expressed in SARS-CoV-2-specific T<sub>SCM</sub> cells, 257 indicating that SARS-CoV-2-specific T<sub>SCM</sub> cells are not exhausted-like progenitors, but bona fide stem-like memory cells. 258

259

Polyfunctional T cells, which exert multiple effector functions simultaneously, play a

critical role in host protection against viral infection<sup>33-35</sup>. For example, polyfunctional CD8<sup>+</sup> T 260 cells are preserved in human immunodeficiency virus-infected long-term non-progressors<sup>34</sup>. 261 In addition, polyfunctional T cell responses are associated with effective control of hepatitis 262C virus (HCV)<sup>35</sup>. It has also been reported that virus-specific polyfunctional T cells can be 263 264 successfully developed by immunization with vaccinia virus<sup>36</sup> and an HCV vaccine<sup>37</sup>. Collectively, polyfunctional memory T cells control viral infection more efficiently than 265 monofunctional T cells. Therefore, generation of polyfunctional memory T cells following 266 natural infection or vaccination is expected to confer protective immunity. In this regard, the 267 sustained polyfunctionality of long-term SARS-CoV-2-specific T cells observed in our study is 268 highly suggestive of long-lasting protective immunity in COVID-19 convalescents. 269 In summary, we conducted a comprehensive analysis of SARS-CoV-2-specific 270 271 memory T cell responses over 8 months post-infection. Our current analysis provides 272valuable information regarding the longevity and differentiation of SARS-CoV-2-specific memory T cells elicited by natural infection. These data add to our basic understanding of 273 memory T cell responses in COVID-19, which aids in establishing an effective vaccination 274 program and epidemiological measurement. 275

#### 276 Methods

#### 277 **Patients and specimens**

In this study, 94 patients with PCR-confirmed SARS-CoV-2 infection were enrolled 278from Ansan Hospital and Chungbuk National University Hospital, Republic of Korea. 279 Peripheral blood was obtained from all patients with SARS-CoV-2 infection. We also obtained 280 281 peripheral blood from seven healthy donors. In six asymptomatic patients, the date of the 282 first admission was regarded as 7 DPSO because the date of the first admission among symptomatic patients was an average 7 DPSO. This study was reviewed and approved by the 283 institutional review board of all participating institutions and conducted according to the 284 principles of the Declaration of Helsinki. Informed consent was obtained from all donors and 285286 patients.

PBMCs were isolated by density gradient centrifugation using Lymphocyte
 Separation Medium (Corning). After isolation, the cells were cryopreserved in fetal bovine
 serum (FBS; Corning) with 10% dimethyl sulfoxide (DMSO; Sigma-Aldrich) until use.

290

#### 291 Ex vivo IFN-γ enzyme-linked immunospot assay

Plates with hydrophobic polyvinylidene difluoride membrane (Millipore, Billerica, 292 293 MA) were coated with 2  $\mu$ g/mL anti-human monoclonal IFN- $\gamma$  coating antibody (clone 1-D1K, 294 Mabtech) overnight at 4°C. The plates were washed with sterile phosphate-buffered saline 295 (PBS) and blocked with 1% bovine serum albumin (Bovogen) for 1 hour at room temperature 296 (RT). 700,000 PBMCs were seeded per well and stimulated with  $1 \mu g/mL$  OLP pools spanning 297 SARS-CoV-2 spike, membrane, and nucleocapsid proteins (Miltenyi Biotec) for 24 hours at 298  $37^{\circ}$ C. We used 10 µg/mL phytohemagglutinin as a positive control and an equimolar amount 299 of DMSO as a negative control. Plates were washed with 0.05% Tween-PBS (Junsei Chemical) 300 and incubated with 0.25  $\mu$ g/mL biotinylated anti-human monoclonal IFN- $\gamma$  antibody (clone 7-B6-1, Mabtech) for 2 hours at RT. After washing, streptavidin-alkaline phosphatase 301 (Invitrogen) was added sequentially. Precipitates were detected with AP color reagent (Bio-302 303 Rad) and the reaction stopped by rinsing with distilled water. Spot-forming units were 304 quantified using an automated ELISpot reader (AID). To quantify SARS-CoV-2-specific responses, spots in the negative control wells were subtracted from the OLP-stimulated 305 306 wells.

0	0	
_ ≺	( )	1
• • •	()	

#### 308 *Multi-color flow cytometry*

309	Cells were stained with fluorochrome-conjugated antibodies for specific surface
310	markers for 10 minutes at RT. Dead cells were excluded using LIVE/DEAD red fluorescent
311	reactive dye (Invitrogen). In intracellular staining experiments, cells were fixed and
312	permeabilized using the FoxP3 staining buffer kit (Invitrogen), and then stained for
313	intracellular markers for 30 minutes at 4°C. Multi-color flow cytometry was performed using
314	an LSR II instrument (BD Biosciences) and the data analyzed in FlowJo software (FlowJo LLC).
315	The fluorochrome-conjugated MHC-I multimers and monoclonal antibodies used in this
316	study are listed in Supplementary Table 2.
317	
318	Activation-induced marker assay
319	PBMCs were blocked with 0.5 $\mu$ g/mL anti-human CD40 mAb (clone HB14, Miltenyi
320	Biotec) in RPMI 1640 supplemented with 10% FBS and 1% penicillin and streptomycin for 15
321	minutes at 37°C. The cells were then cultured in the presence of 1 $\mu\text{g}/\text{mL}$ SARS-CoV-2 OLP
322	pools and 1 $\mu\text{g}/\text{mL}$ anti-human CD28 and CD49d mAbs (clone L293 and L25, respectively, BD
323	Biosciences) for 24 hours. Stimulation with an equal concentration of DMSO in PBS was
324	performed as a negative control.
325	
326	MHC-I multimer staining
327	PBMCs were stained with APC-conjugated MHC-I SARS-CoV-2 S269 pentamer
328	(Proimmune), IAV MP58 dextramer (Immudex), or CMV pp65495 dextramer (Immudex) for 15
329	minutes at RT and washed twice. Additional surface markers were stained using the
330	protocols described above.
331	
332	Stimulation for intracellular cytokine staining
333	PBMCs were cultured in the presence of SARS-SoV-2 OLP pools and 1 $\mu g/mL$ anti-
334	human CD28 and CD49d mAbs for 6 hours at 37°C. Brefeldin A (GolgiPlug, BD Biosciences)
335	and monensin (GolgiStop, BD Biosciences) were added 1 hour after the initial stimulation.
336	

337 Proliferation assays

PBMCs were labeled using the CellTrace<sup>™</sup> Violet Cell Proliferation Kit (Invitrogen) at 338 a concentration of 1.0 x 10<sup>6</sup> cells/mL for 20 minutes at 37°C. We then added 1% FBS-PBS to 339 the cells for 5 minutes at RT to quench unbound dyes. Cells were washed and cultured in 340 RPMI 1640 (Corning) containing 10% FBS (Corning) and 1% penicillin-streptomycin 341 (Welgene) at a concentration of 500,000 cells per well in the presence of 1  $\mu$ g/mL SARS-CoV-342 343 2 spike peptide pools and 1 µg/mL anti-human CD28 and CD49d mAbs (clone L293 and L25 344 respectively, BD Biosciences) for 120 hours. Stimulation with an equal concentration of DMSO in PBS was performed as a negative control. After incubation, cells were harvested 345 and stained with antibodies for analysis by flow cytometry. 346

347

348

#### 8 Data quantification and statistical analysis

349 Data were calculated as background-subtracted data. Background-subtracted data 350 were derived by subtracting the value after DMSO stimulation. When three stimuli were 351 combined, the value after each stimulation was combined and we subtracted triple the 352 value derived from DMSO stimulation.

Statistical analyses were performed using GraphPad Prism version 9 for Windows (GraphPad Software). Significance was set at p<0.05. The Wilcoxon signed-rank test was used to compare data between two paired groups. In addition, the Kruskal-Wallis test with Dunns' multiple comparisons test was used to compare non-parametric data between multiple unpaired groups. To assess the significance of correlation, the Spearman correlation test was used. In cross-sectional analyses, a non-parametric local regression (LOESS) function was employed with 95% confidence interval.

#### 360 Data availability

- 361 Data relating to the findings of this study are available from the corresponding author upon
- 362 reasonable request.
- 363

#### 364 Acknowledgments

- 365 This work was supported by the Samsung Science and Technology Foundation under Project
- 366 Number SSTF-BA1402-51, and the Mobile Clinic Module Project funded by KAIST.
- 367

#### 368 Author Contributions

- 369 J.H.J., M.-S.R., H.W.J., W.S.C., and E.-C.S. designed the research. H.K.C., J.H.J., H.S., D.W.P.,
- H.W.J., and W.S.C. collected clinical specimens. J.H.J., M.-S.R., and M.S. performed
- experiments. J.H.J., M.-S.R., S.-H.P., and E.-C.S. analyzed the results. J.H.J., M.-S.R. and E.-
- 372 C.S. wrote the manuscript.
- 373

#### **Competing Interests**

375 The authors have no competing interests.

#### 376 **References**

010		
377	1	Huang, C. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.
378		Lancet <b>395</b> , 497-506 (2020).
379	2	World Health Organization. COVID-19 Weekly Epidemiological Update-19 January 2020
380		https://www.who.int/publications/m/item/weekly-epidemiological-update-19-january-2020 (2020).
381	3	Lee, J. S. et al. Immunophenotyping of COVID-19 and influenza highlights the role of type I interferons
382		in development of severe COVID-19. Sci. Immunol. 5, eabd1554 (2020).
383	4	Lee, J. S. & Shin, E. C. The type I interferon response in COVID-19: implications for treatment. Nat. Rev.
384		Immunol. <b>20</b> , 585-586 (2020).
385	5	Grifoni, A. et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19
386		Disease and Unexposed Individuals. Cell 181, 1489-1501.e15 (2020).
387	6	Le Bert, N. et al. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected
388		controls. <i>Nature</i> <b>584</b> , 457-462 (2020).
389	7	Peng, Y. et al. Broad and strong memory CD4(+) and CD8(+) T cells induced by SARS-CoV-2 in UK
390		convalescent individuals following COVID-19. Nat. Immunol. 21, 1336-1345 (2020).
391	8	Sekine, T. et al. Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-
392		19. <i>Cell</i> <b>183</b> , 158-168.e14 (2020).
393	9	Rodda, L. B. et al. Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19. Cell
394		<b>184</b> , 169-183.e17 (2020).
395	10	McMahan, K. et al. Correlates of protection against SARS-CoV-2 in rhesus macaques. Nature,
396		doi:10.1038/s41586-020-03041-6 (2020).
397	11	Ng, O. W. et al. Memory T cell responses targeting the SARS coronavirus persist up to 11 years post-
398		infection. Vaccine <b>34</b> , 2008-2014 (2016).
399	12	Zhao, J. X. et al. Recovery from the Middle East respiratory syndrome is associated with antibody and T
400		cell responses. Sci. Immunol. 2, eaan5393 (2017).
401	13	Tang, F. et al. Lack of peripheral memory B cell responses in recovered patients with severe acute
402		respiratory syndrome: a six-year follow-up study. J. Immunol. 186, 7264-7268 (2011).
403	14	Dan, J. M. et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection.
404		Science, doi:10.1126/science.abf4063 (2021).
405	15	Gattinoni, L. et al. A human memory T cell subset with stem cell-like properties. Nat. Med. 17, 1290-
406		1297 (2011).
407	16	Gattinoni, L., Speiser, D. E., Lichterfeld, M. & Bonini, C. T memory stem cells in health and disease. Nat.
408		Med. <b>23</b> , 18-27 (2017).
409	17	Fuertes Marraco, S. A. et al. Long-lasting stem cell-like memory CD8+ T cells with a naive-like profile
410		upon yellow fever vaccination. Sci. Transl. Med. 7, 282ra248 (2015).
411	18	Akondy, R. S. et al. Origin and differentiation of human memory CD8 T cells after vaccination. Nature
412		<b>552</b> , 362-367 (2017).

413	19	National Institutes of Health. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019
414		(COVID-19) Treatment Guidelines. https://www.covid19treatmentguidelines.nih.gov (2020).
415	20	Rydyznski Moderbacher, C. et al. Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-
416		19 and Associations with Age and Disease Severity. Cell 183, 996-1012.e19 (2020).
417	21	Morou, A. et al. Altered differentiation is central to HIV-specific CD4(+) T cell dysfunction in
418		progressive disease. Nat. Immunol. <b>20</b> , 1059-1070 (2019).
419	22	Shomuradova, A. S. et al. SARS-CoV-2 Epitopes Are Recognized by a Public and Diverse Repertoire of
420		Human T Cell Receptors. Immunity 53, 1245-1257.e5 (2020).
421	23	Rha, M. S. et al. PD-1-Expressing SARS-CoV-2-Specific CD8(+) T Cells Are Not Exhausted, but Functional
422		in Patients with COVID-19. Immunity 54, 44-52.e3 (2021).
423	24	Galletti, G. et al. Two subsets of stem-like CD8(+) memory T cell progenitors with distinct fate
424		commitments in humans. <i>Nat. Immunol.</i> <b>21</b> , 1552-1562 (2020).
425	25	Schwarzkopf, S. et al. Cellular Immunity in COVID-19 Convalescents with PCR-Confirmed Infection but
426		with Undetectable SARS-CoV-2-Specific IgG. Emerg. Infect. Dis. 27, doi:10.3201/2701.203772 (2020).
427	26	Ibarrondo, F. J. et al. Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19. N.
428		Engl. J. Med. <b>383</b> , 1085-1087 (2020).
429	27	Isho, B. et al. Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in
430		COVID-19 patients. Sci. Immunol. 5, eabe5511 (2020).
431	28	Long, Q. X. et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat.
432		Med. <b>26</b> , 1200-1204 (2020).
433	29	Mateus, J. et al. Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans. Science
434		<b>370</b> , 89-94 (2020).
435	30	Nelde, A. et al. SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell
436		recognition. Nat. Immunol. 22, 74-85 (2020).
437	31	Woldemeskel, B. A. et al. Healthy donor T cell responses to common cold coronaviruses and SARS-
438		CoV-2. J. Clin. Invest. 130, 6631-6638 (2020).
439	32	Braun, J. et al. SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19. Nature 587,
440		270-274 (2020).
441	33	Almeida, J. R. et al. Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity,
442		polyfunctionality, and clonal turnover. J. Exp. Med. 204, 2473-2485 (2007).
443	34	Betts, M. R. et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T
444		cells. <i>Blood</i> <b>107</b> , 4781-4789 (2006).
445	35	Ciuffreda, D. et al. Polyfunctional HCV-specific T-cell responses are associated with effective control of
446		HCV replication. Eur. J. Immunol. <b>38</b> , 2665-2677 (2008).
447	36	Precopio, M. L. et al. Immunization with vaccinia virus induces polyfunctional and phenotypically
448		distinctive CD8(+) T cell responses. J. Exp. Med. 204, 1405-1416 (2007).
449	37	Park, S. H. et al. Successful vaccination induces multifunctional memory T-cell precursors associated

with early control of hepatitis C virus. Gastroenterology 143, 1048-1060.e4 (2012).

#### 451 **Figure Legends**

Fig. 1. SARS-CoV-2-specific IFN- $\gamma$  responses over 8 months post-infection. PBMC samples 452 (n=135) from individuals with SARS-CoV-2 infection (n=76) were stimulated with OLPs of S, 453M, or N (1  $\mu$ g/mL) for 24 h and the spot-forming units of IFN- $\gamma$ -secreting cells examined by 454ELISpot. **a**, Scatter plots showing the relationship between DPSO and IFN- $\gamma$  responses. The 455 456 black line is a LOESS smooth nonparametric function, and the grey shading represents the 95% confidence interval. **b**, The composition of S-, M-, or N-specific IFN- $\gamma$  responses among 457the total IFN- $\gamma$  responses in each individual. **c**, IFN- $\gamma$  responses were compared between T1 458 (n=46, 31 - 99 DPSO), T2 (n=37, 100 - 199 DPSO), and T3 (n=23, 200 - 254 DPSO). Data are 459 presented as median and interquartile range (IQR). **d,e**, IFN- $\gamma$  responses were analyzed in 460 longitudinally tracked samples (n=82) from 30 individuals. d, Scatter plots showing the 461 462 relationship between DPSO and IFN-y responses. e, IFN-y responses was compared between 463 paired samples at two time points (n=14; t1, 31 - 100 DPSO; t2, 200 - 254 DPSO). Statistical 464 analysis was performed using the Kruskal-Wallis test with Dunns' multiple comparisons test (c) or the Wilcoxon signed-rank test (e). n.s, not significant. 465

466

Fig. 2. Kinetics of SARS-CoV-2-specific activation-induced marker (AIM)<sup>+</sup> T cells. PBMC 467 samples (n=125) from individuals with SARS-CoV-2 infection (n=69) were stimulated with 468 OLPs of S, M, or N (1  $\mu$ g/mL) for 24 h. The frequency of AIM<sup>+</sup> (CD137<sup>+</sup>OX40<sup>+</sup>) cells among 469 470 CD4<sup>+</sup> T cells and the frequency of AIM<sup>+</sup> (CD137<sup>+</sup>CD69<sup>+</sup>) cells among CD8<sup>+</sup> T cells were 471 analyzed. **a,b**, Representative flow cytometry plots showing the frequency of AIM<sup>+</sup> cells 472 among CD4<sup>+</sup> (**a**) or CD8<sup>+</sup> (**b**) T cells. **c**, Scatter plots showing the relationship between DPSO and the frequency of AIM<sup>+</sup> cells among CD4<sup>+</sup> (left) or CD8<sup>+</sup> (right) T cells. The black is a LOESS 473 474smooth nonparametric function, and the grey shading represents the 95% confidence interval. 475

476

477 Fig. 3. Differentiation status of SARS-CoV-2-specific AIM<sup>+</sup> T cells. a-d, PBMC samples
478 (n=124) from individuals with SARS-CoV-2 infection (n=68) were stimulated with OLPs of S,

479 M, or N (1 μg/mL) for 24 h and the expression of CCR7 and CD45RA was analyzed in AIM<sup>+</sup>

480 (CD137<sup>+</sup>OX40<sup>+</sup>) CD4<sup>+</sup> (**a**,**c**) and AIM<sup>+</sup> (CD137<sup>+</sup>CD69<sup>+</sup>) CD8<sup>+</sup> (**b**,**d**) T cells. **a**,**b**, Gating strategies

481 for identifying each memory subset among AIM<sup>+</sup>CD4<sup>+</sup> (a) or AIM<sup>+</sup>CD8<sup>+</sup> (b) T cells. c,d, Scatter

482plots showing the relationship between DPSO and the proportion of the indicated subsets among AIM<sup>+</sup>CD4<sup>+</sup> (c) or AIM<sup>+</sup>CD8<sup>+</sup> (d) T cells. e, PBMC samples (n=47) from individuals with 483 SARS-CoV-2 infection (n=34) were stimulated with OLPs of S, M, or N (1 µg/mL) for 24 h and 484the frequency of T<sub>SCM</sub> (CCR7<sup>+</sup>CD45RA<sup>+</sup>CD95<sup>+</sup>) cells was analyzed in AIM<sup>+</sup>CD4<sup>+</sup> (upper) and 485AIM<sup>+</sup>CD8<sup>+</sup> (lower) T cells. Left, The gating strategy for identifying T<sub>SCM</sub> cells. Right, Scatter 486 487plots showing the relationship between DPSO and the proportion of T<sub>SCM</sub> cells among 488AIM<sup>+</sup>CD4<sup>+</sup> or AIM<sup>+</sup>CD8<sup>+</sup> T cells. The black line is a LOESS smooth nonparametric function, and the grey shading represents the 95% confidence interval (**c,d,e**). 489

490

Fig. 4. Frequency and differentiation status of SARS-CoV-2-specific MHC-I multimer<sup>+</sup> T cells. 491 492 PBMC samples (n=15) from individuals with SARS-CoV-2 infection (n=11) were analyzed by flow cytometry. a, Representative flow cytometry plots showing the ex vivo detection of 493 494 SARS-CoV-2  $S_{269}$  multimer<sup>+</sup>CD8<sup>+</sup> T cells in the gate of CD3<sup>+</sup> T cells. **b**, Scatter plot showing the 495relationship between DPSO and the frequency of SARS-CoV-2 S269 multimer<sup>+</sup> cells among total CD8<sup>+</sup> T cells. Samples from the same patient are connected by solid lines. c,d, The 496 expression of CCR7, CD45RA, and CD95 was analyzed in SARS-CoV-2 S<sub>269</sub> multimer<sup>+</sup>CD8<sup>+</sup> T 497 cells. IAV MP<sub>58</sub> multimer<sup>+</sup> (n=5) and CMV pp65<sub>495</sub> multimer<sup>+</sup> (n=6) cells from the PBMCs of 498 healthy donors were also analyzed. Representative flow cytometry plots (c) show the 499 500 proportion of the indicated subsets among multimer<sup>+</sup> cells, and scatter plots (**d**) show the 501 relationship between DPSO and the proportion of the indicated subsets among SARS-CoV-2 502 S269 multimer<sup>+</sup> cells. Samples from the same patient are connected by solid lines. Summary 503 data showing the proportion of the indicated subsets among IAV multimer<sup>+</sup> and CMV 504 multimer<sup>+</sup> cells are also presented (d). Horizontal lines represent median. e, A representative flow cytometry plot (upper) and summary data (lower) showing the percentage of PD-505 1<sup>+</sup>TIGIT<sup>+</sup> cells among SARS-CoV-2 S<sub>269</sub> multimer<sup>+</sup> cells and total CD8<sup>+</sup> T cells. Statistical 506 analysis was performed using the Wilcoxon signed-rank test (e). \*\*P < 0.01. 507 508

509 Fig. 5. Polyfunctionality and proliferation capacity of SARS-CoV-2-specific T cells. a-d,

PBMC samples (n=90) from individuals with SARS-CoV-2 infection (n=39) were stimulated 510

with OLPs of S, M, or N (1  $\mu$ g/mL) for 6 h. Intracellular cytokine staining was performed to 511

examine the frequency of polyfunctional cells exhibiting positivity for  $\geq 2$  effector functions 512

among SARS-CoV-2-specific CD4<sup>+</sup> and CD8<sup>+</sup> T cells. **a**, Representative flow cytometry plots 513 showing the frequency of polyfunctional cells among CD4<sup>+</sup> (left) and CD8<sup>+</sup> (right) T cells. b, 514 Scatter plots showing the relationship between DPSO and the frequency of polyfunctional 515cells among SARS-CoV-2-specific CD4<sup>+</sup> (upper) or CD8<sup>+</sup> (lower) T cells. The black line is a 516 LOESS smooth nonparametric function, and the grey shading represents the 95% confidence 517 518 interval. c, The fraction of polyfunctional cells among SARS-CoV-2-specific CD4<sup>+</sup> (left) or CD8<sup>+</sup> (right) T cells was compared between T1 (n=17, 31 - 99 DPSO), T2 (n=39, 100 - 199 DPSO), 519 and T3 (n=25, 200 - 254 DPSO). Data are presented as median and IQR. d, Pie charts showing 520 the fraction of cells positive for a given number of functions among SARS-CoV-2-specific 521 CD4<sup>+</sup> (left) or CD8<sup>+</sup> (right) T cells. Each arc in the pie chart represents the indicated function. 522e, CTV-labeled PBMCs (n=11) obtained after 200 DPSO were stimulated with S OLP pool (1 523  $\mu$ g/mL) for 120 h and the frequency of CTV<sup>low</sup> and Ki-67<sup>+</sup> cells among CD4<sup>+</sup> T cells was 524 525 analyzed. Representative plots (upper) and summary data (lower) are presented. Statistical 526 analysis was performed using the Kruskal-Wallis test with Dunns' multiple comparisons test (c) or the Wilcoxon signed-rank test (e). n.s, not significant, \*\*\*P < 0.001. 527





CD45RA-APC-Cy7 +

CD95-PE



Days post-symptom onset





Parameter	COVID-19 (n=94)
Age(years)	19-96 (median 39, IQR 29)
Gender (F/M)	55/39
Peak disease severity <sup>a</sup>	
Asymptomatic, n	6 (6.4%)
Mild, n	44 (46.8%)
Moderate, n	23 (24.5%)
Severe, n	13 (13.8%)
Critical, n	8 (8.5%)
DPSO at sample collection	1-254 (median 94, IQR 93)
Blood collection	
Multiple time points, n	38
2	16
3	16
4	6
Single time point, n	56
Assays	Total 160 samples
IFN-γ ELISpot assays	135 samples (n=76)
ICS	90 samples (n=39)
AIM assays	125 samples (n=69)
MHC-I multimer staining	15 samples (n=11)
Proliferation assays	11 samples (n=11)

### Supplementary Table 1. Characteristics of enrolled patients

IQR, interquartile range; DPSO, days post-symptom onset; ELISpot, enzymelinked immunospot; ICS, intracellular cytokine staining; AIM, activationinduced marker; CTV, CellTrace Violet.

<sup>a</sup>Disease severity was defined by the NIH severity of illness categories.

### Supplementary Table 2. Flow cytometry reagents

REAGENT	SOURCE	IDENTIFIER
FITC Anti-human CD107a (clone H4A3)	BD Biosciences	#555800
APC Anti-human CD137 (clone 4B4-1)	BD Biosciences	#550890
BV421 Anti-human CD137 (clone 4B4-1)	BD Biosciences	#564091
PE-CF594 Anti-human CD14 (clone ΜφΡ9)	BD Biosciences	#562335
APC Anti-human CD154 (clone TRAP1)	BD Biosciences	#555702
PE-CF594 Anti-human CD19 (clone HIB19)	BD Biosciences	#562294
BV510 Anti-human CD27 (clone L128)	BD Biosciences	#563092
BV510 Anti-human CD3 (clone UCHT1)	BD Biosciences	#563109
BV786 Anti-human CD3 (clone UCHT1)	BD Biosciences	#565491
BV605 Anti-human CD4 (clone RPA-T4)	BD Biosciences	#562658
FITC Anti-human CD4 (clone RPA-T4)	BD Biosciences	#555346
PerCP™Cy5.5 Anti-human CD4 (clone RPA-T4)	BD Biosciences	#560650
AF700 Anti-human TNF (clone Mab11)	BD Biosciences	#557996
BB515 Anti-human CD45RO (clone UCHL1)	BD Biosciences	#564529
PE-Cy7 Anti-human CD69 (clone FN50)	BD Biosciences	#557745
APC-Cy7 Anti-human CD8 (clone SK1)	BD Biosciences	#560179
BV605 Anti-human CD8 (clone SK1)	BD Biosciences	#564116
BV711 Anti-human CD8 (clone RPA-T8)	BD Biosciences	#563677
PE Anti-human CD95 (clone DX2)	BD Biosciences	#555674
PE-Cy7 Anti-human IFN-γ (clone 4S.B3)	BD Biosciences	#557844
APC Anti-human IL-2 (clone MQ1-17H12)	BD Biosciences	#554567
BV786 Anti-human Ki-67 (clone B56)	BD Biosciences	#563756
PerCP™Cy5.5 Anti-human CCR7 (clone G043H7)	BioLegend	#353220
PE Anti-human CD137 (clone 4B4-1)	BioLegend	#309804
APC Anti-human CD3 (clone HIT3a)	BioLegend	#300312
APC-Cy7 Anti-human CD45RA (clone HI100)	BioLegend	#304128
FITC Anti-human CD8 (clone RPA-T8)	BioLegend	#301050
BV421 Anti-human OX40 (clone Ber-ACT35)	BioLegend	#350014
BV421 Anti-human PD-1 (clone EH12.2H7)	BioLegend	#329920
PE-Cy7 Anti-human TIGIT (clone MBSA43)	Invitrogen	#25-9500-42
APC YLQPRTFLL (SARS-CoV-2 S269) HLA-A*0201 Pentamer	Proimmune	#4339
APC GILGFVFTL (IAV MP <sub>58</sub> ) HLA-A*0201 Dextramer	Immudex	#WB2161
APC NLVPMVATV (CMV pp65495) HLA-A*0201 Dextramer	Immudex	#WB2132



Extended Data Fig. 1. Proportion of S-, M-, and N-specific IFN- $\gamma$  responses among total IFN- $\gamma$  responses. PBMC samples from individuals with SARS-CoV-2 infection were stimulated with OLPs of S, M, or N (1 µg/mL) for 24 h and spot-forming units of IFN- $\gamma$ -secreting cells were examined by ELISpot. Pie charts showing the proportion of S-, M-, and N-specific IFN- $\gamma$  responses among the total IFN- $\gamma$  responses in T1 (n=46, 31 - 99 DPSO), T2 (n=37, 100 - 199 DPSO), and T3 (n=23, 200 - 254 DPSO).



Extended Data Fig. 2. Correlation between the frequency of CD137<sup>+</sup>OX40<sup>+</sup> cells and the frequencies of alternative AIM<sup>+</sup> cells (OX40<sup>+</sup>CD154<sup>+</sup> or CD137<sup>+</sup>CD154<sup>+</sup> cells) among CD4<sup>+</sup> T cells. PBMC samples from individuals with SARS-CoV-2 infection were stimulated with OLPs of S, M, or N (1  $\mu$ g/mL) for 24 hours, and the correlation between the frequency of CD137<sup>+</sup>OX40<sup>+</sup> cells and the frequencies of alternative AIM<sup>+</sup> cells (OX40<sup>+</sup>CD154<sup>+</sup> or CD137<sup>+</sup>CD154<sup>+</sup> cells) among CD4<sup>+</sup> T cells (OX40<sup>+</sup>CD154<sup>+</sup> or CD137<sup>+</sup>CD154<sup>+</sup> cells) among CD4<sup>+</sup> T cells was analyzed (n=78). Statistical analysis was performed using the Spearman correlation test.



**Extended Data Fig. 3. Correlation of the frequency of AIM<sup>+</sup> cells between CD4<sup>+</sup> and CD8<sup>+</sup> T cells.** PBMC samples from individuals with SARS-CoV-2 infection were stimulated with OLPs of S, M, or N (1  $\mu$ g/mL) for 24 h and the correlation between the frequency of AIM<sup>+</sup> (CD137<sup>+</sup>OX40<sup>+</sup>) cells among CD4<sup>+</sup> T cells and AIM<sup>+</sup> (CD137<sup>+</sup>CD69<sup>+</sup>) cells among CD8<sup>+</sup> T cells was analyzed (n=125). Statistical analysis was performed using the Spearman correlation test.



Extended Data Fig. 4. Frequency of  $T_{SCM}$  cells among SARS-CoV-2-specific T cells according to days post-symptom onset. a,b, PBMC samples from individuals with SARS-CoV-2 infection were stimulated with OLPs of S, M, or N (1 µg/mL) for 24 h and the frequency of  $T_{SCM}$  (CCR7<sup>+</sup>CD45RA<sup>+</sup>CD95<sup>+</sup>) cells was analyzed among AIM<sup>+</sup> (CD137<sup>+</sup>OX40<sup>+</sup>) CD4<sup>+</sup> (a) and AIM<sup>+</sup> (CD137<sup>+</sup>CD69<sup>+</sup>) CD8<sup>+</sup> T cells (b). The frequencies of  $T_{SCM}$  cells were compared between T1 (n=12, 31 - 99 DPSO), T2 (n=14, 100 - 199 DPSO), and T3 (n=20, 200 - 254 DPSO). Data are presented as median and IQR. Statistical analysis was performed using the Kruskal-Wallis test with Dunns' multiple comparisons test. n.s, not significant.